GlassScriptPhysician profile
Glen A Rountree
NPI 1144222100
$456.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $54.17 · 2021: $31.97 · 2022: $40.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $166.00 | 2019-2021 | |
| Neotract INC. | $84.18 | 2019 | |
| Abbvie INC. | $27.92 | 2019-2020 | |
| Blue Earth Diagnostics | $26.80 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $26.07 | 2019 | |
| Procept Biorobotics Corporation | $20.56 | 2021 | |
| Janssen Scientific Affairs, LLC | $18.76 | 2019 | |
| Siemens Medical Solutions USA, INC. | $17.51 | 2019 | |
| Allergan, INC. | $16.70 | 2019 | |
| Cook Medical LLC | $15.11 | 2022 | |
| Axonics, INC. | $12.79 | 2022 | |
| Medtronic, INC. | $12.71 | 2022 | |
| Coloplast Corp | $11.23 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Rountree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.